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Abstract Spinocerebellar ataxia type 2 (SCA2) and amyotro-
phic lateral sclerosis (ALS) are neurodegenerative disorders,
caused or modified by an unstable CAG-repeat expansion in
the SCA2 gene, which encodes a polyglutamine (polyQ) do-
main expansion in ataxin-2 (ATXN2). ATXN2 is an RNA-
binding protein and interacts with the poly(A)-binding protein
PABPC1, localizing to ribosomes at the rough endoplasmic
reticulum. Under cell stress, ATXN2, PABPC1 and small ri-
bosomal subunits are relocated to stress granules, where
mRNAs are protected from translation and from degradation. It
is unknown whether ATXN2 associates preferentially with spe-
cific mRNAs or how it modulates RNA processing. Here, we
investigated the RNA profile of the liver and cerebellum from
Atxn2 knockout (Atxn2−/−) mice at two adult ages, employing
oligonucleotidemicroarrays. Prominent increases were observed
for Lsm12/Paip1 (>2-fold), translation modulators known as
protein interactor/competitor of ATXN2 and for Plin3/Mttp
(>1.3-fold), known as apolipoprotein modulators in agreement
with the hepatosteatosis phenotype of the Atxn2−/− mice. Con-
sistent modest upregulations were also observed for many fac-
tors in the ribosome and the translation/secretion apparatus.
Quantitative reverse transcriptase PCR in liver tissue validated
>1.2-fold upregulations for the ribosomal biogenesis modulator
Nop10, the ribosomal components Rps10, Rps18, Rpl14, Rpl18,
Gnb2l1, the translation initiation factors Eif2s2, Eif3s6, Eif4b,
Pabpc1 and the rER translocase factors Srp14, Ssr1, Sec61b.
Quantitative immunoblots substantiated the increased abun-
dance of NOP10, RPS3, RPS6, RPS10, RPS18, GNB2L1 in
SDS protein fractions, and of PABPC1. In mouse embryonal
fibroblasts, ATXN2 absence also enhanced phosphorylation of
the ribosomal protein S6 during growth stimulation, while
impairing the rate of overall protein synthesis rates, suggesting
a block between the enhanced translation drive and the impaired
execution. Thus, the physiological role of ATXN2 subtly mod-
ifies the abundance of cellular translation factors as well as glob-
al translation.
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Introduction
Spinocerebellar ataxia type 2 (SCA2) is an autosomal domi-
nantly inherited neurodegenerative disorder caused by large
expansions in an unstable polyglutamine domain within the
protein ataxin-2 (ATXN2), probably through a toxic gain-of-
function mechanism [1–3]. Intermediate size polyglutamine
expansions within ATXN2 were more recently implicated as
risk factor of the motor neuron disease amyotrophic lateral
sclerosis (ALS), of the basal ganglia tauopathy progressive
supranuclear palsy (PSP) and of the preferential midbrain de-
generation in Parkinson’s disease (PD) [4–7]. A recent survey
of modif ier genes in Saccharomyces cerevis iae ,
Caenorhabditis elegans and Drosophila melanogaster con-
cluded that ataxin-2 orthologues are generic modifiers that
affect multiple if not all neurodegenerative diseases [8]. Fur-
thermore, the deletion of Atxn2 in mouse as well as single
nucleotide polymorphisms at the chromosomal ATXN2 locus
in human implicated ATXN2 in hepatosteatosis, obesity, dys-
lipidemia, insulin resistance, diabetes mellitus and arterial hy-
pertension [9–17]. Thus, ataxin-2 appears to regulate basic
metabolic features, and its chronic loss or accumulation/
aggregation result in age-associated diseases.
ATXN2 was described as a cytoplasmic protein with allelic
splicing and an age-dependent expression increase, containing
1312 amino acid residues and migrating at a molecular mass
of about 150 kDa [18–20]. However, recently, its translation
was reported to depend on a methionine start codon 160 ami-
no acids further down, only 5 amino acids upstream from the
polyglutamine domain [21]. Its expression was observed
mainly in the brain in specific neuronal populations, for ex-
ample in cerebellar and cerebral cortex, but also in several
non-neuronal tissues such as the skeletal muscle, kidney, pros-
tate, thyroid gland and liver [19]. A role of ATXN2 in trophic
signalling through direct interaction with the receptor-
mediated endocytosis machinery was discovered through pro-
tein interaction studies [22–25]. Its subcellular localization to
Golgi organelles was claimed initially on the basis of recom-
binant overexpression. Later studies of endogenous ATXN2
found it to be associated with polysomes and localized it
mainly at the rough endoplasmic reticulum (rER). It was rare-
ly observed at the plasma membrane or shuttling to the nucle-
us in some cells [26–31].
Protein interaction studies found this co-localization of
ATXN2 with ribosomes to depend both on the globular
Lsm/Lsm-AD domains of ATXN2 that are thought to mediate
RNA processing, and on the PAM2 motif of ATXN2 that is
known to mediate direct protein interaction with poly(A)-
binding protein PABPC1 [29, 32]. PABPC1 acts during trans-
lation, simultaneously binding the 3′-poly(A) tail of mRNAs
and the 5′-associated translation initiation factor eIF4G, thus
promoting mRNA circularisation as an essential step in trans-
lation initiation [29, 33–35]. Interestingly, opposing roles for
the two interactor proteins were found in the yeast
S. cerevisiae, where the deletion of the ATXN2 orthologue
Pbp1 suppresses the lethality associated with a PAB1 deletion
[36]. Opposing roles were also found in D. melanogaster fly
models of ataxin-3-induced neurodegeneration, where
ATXN2 overexpression potentiates the phenotype, while a
phenotype rescue was observed after PABPC1 overexpression
[37]. To date, it remains unclear how ATXN2 modulates the
PABPC1 function.
Lsm domains as those within ATXN2 are highly conserved
in proteins that are involved in important processes of RNA
metabolism such as RNA modification, splicing and degrada-
tion [29, 34, 38]. The putative role of ATXN2 for RNA pro-
cessing is further substantiated by its interaction with at least
five RNA-binding proteins: (i) ataxin-2 binding protein 1
(A2BP1 or RBFOX1) binds to the C-terminus of ATXN2
and has an RNA recognition motif that is highly conserved
among RNA-binding proteins [39]. (ii) ATXN2 was found to
associate with DEAD/H-box RNA helicase DDX6, a compo-
nent of stress granules and P-bodies, thus influencing the stor-
age of mRNA in periods of stalled translation as well as the
degradation of mRNAs [30]. (iii) The TDP-43 protein with its
two RRM (RNA recognition motifs) shows genetic interac-
tion with ATXN2 and associates with the ATXN2 protein in a
complex that depends on RNA binding [4]. (iv) The RRM-
containing FUS protein interacts with ATXN2 both at the
protein level as well as genetically [40]. (v) The FMRP protein
is associated with polysomes as a translational repressor and
was recently observed to interact with ATXN2 in long-term
neuronal habituation processes [41].
Beyond this indirect evidence for a role of ATXN2 in RNA
processing, a direct interaction with RNA could recently be
demonstrated experimentally [42]. At least in the case of the
PERIOD clock gene mRNA, ATXN2 activates translation
through enhanced association between PABP and the circadi-
an factor TYF, thus signalling Bsubjective night^ and sustain-
ing the circadian clock [43, 44]. Interestingly, ATXN2 was
also implicated in microRNA processing during the habitua-
tion of olfactory synapses [41, 45].
Yeast evidence elucidated its function for RNAs further.
The ATXN2 yeast orthologue Pbp1 was reported to protect
the full length of the poly(A) tail of mRNAs and to act as
negative regulator of poly(A) nuclease (PAN) activity [36,
46]. Additional studies showed that the deletion of Pbp1 was
able to rescue the deleterious growth of double mutants that
harboured the deletion of a deadenylase (CCR4 or POP2)
together with the deletion of the RNA-binding protein
KHD1 [47]. This effect was also achieved by deletion of the
ribosomal proteins Rpl12a/b, with Pbp1 being found to inter-
act with these ribosomal subunits [47]. It is still unclear how
RNA processing is modulated by the interaction of Pbp1 with
Lsm12, a protein with an N-terminal Lsm domain that has
been suggested to play a role in mRNA degradation or tRNA
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splicing [34, 48–50]. Pbp1 overexpression or heat stress in-
duce stress granule formation and sequester the TORC1 ki-
nase complex, thus blunting its signalling that drives cell
growth upon nutrient availability [51, 52].
In periods of cell stress, the immediate suppression of pro-
tein synthesis is accompanied by formation of transient cyto-
plasmic foci known as stress granules (SGs), where untrans-
lated mRNAs accumulate together with 40S small ribosomal
subunits, PABPC1 and translation initiation factors [53], as
well as by enlargement of mRNA degrading P-bodies. In vitro
investigations usually trigger SG formation by glucose depri-
vation or by the administration of oxidative stress via arsenite.
ATXN2 was observed to relocalize to SGs together with
PABPC1 and associate with P-bodies. Investigation of human
cells showed ATXN2 deficiency to prevent SG assembly,
while its overexpression reduced the number of P-bodies per
cell [30].
To determine whether ATXN2-dependent altered RNA
processing modulates steady-state levels of specific mRNAs,
the present study used tissues from Atxn2 knockout (Atxn2−/−
or KO) and wild-type (WT) mice, performing unbiased global
mRNA profiling. A pattern of consistent upregulations of
ribosome/translation-related transcripts was prominent in both
approaches. In view of the known association of ATXN2 with
the translation initiation factor PABPC1, the validation of the-
se translation-relevant factors and the study of global protein
synthesis changes in Atxn2−/− embryonal fibroblasts were pri-
oritized for this manuscript.
Results
Screening of the transcriptome by microarrays: liver
and cerebellum profile in Atxn2−/− mice until age 6 months
The transcriptome profiles were analysed for 4 conditions
with a total of 32 microarray chips. In view of the relevance
of ATXN2 for the age-progressive disease hepatosteatosis and
SCA2, we used the tissues liver and cerebellum, each collect-
ed at ages 6 or 24 weeks (always from 4 Atxn2−/− versus 4
Atxn2+/+ mice). Atxn2 is known to show strong physiological
expression not only in several neuronal populations such as
cerebellar Purkinje cells and spinal motor neurons, but also in
liver and in the hepatocyte-like tumor cells Hep G2. The ab-
sence of Atxn2 transcripts from the KO tissues was confirmed
by the relevant Affymetrix oligonucleotide spots
1419866_s_at, 1460653_at, 1438143_s_at, 1438144_x_at,
1459363_at and 1443516_at. Automated bioinformatic anal-
yses showed 70 additional non-anonymous genes with signif-
icant mRNA level upregulation and consistency for all 4 con-
ditions (Suppl. Table 1). Most of the altered factors have roles
in RNA translation/processing, ER secretion, lipid metabo-
lism, growth/adhesion or cytoskeletal dynamics. Several
observations were in excellent agreement with previous
knowledge on ATXN2 biology: (i) More than 6-fold increases
were observed by two oligonucleotide spots for Paip1, a trans-
lation activator that binds to the PAM2-domain of PABPC1
just like ATXN2 [54, 55]; (ii) more than 2-fold increases were
documented by two oligonucleotide spots for Lsm12, an
mRNA degradation or tRNA splicing factor that is known to
interact and colocalize with the ATXN2-ortholog Pbp1 in
yeast [48, 52]; (iii) a 1.3-fold increase was detected for
Sh3kbp1 (CIN85), an interactor protein of ATXN2 in the re-
ceptor endocytosis complex [24]; (iv) a 1.3-fold increase was
found also for Plin3, a factor important for the biogenesis of
lipid droplets [56], which are known to accumulate inAtxn2−/−
liver; (v) a 1.4-fold increase was shown by two oligonucleo-
tide spots for Mttp, a factor required for the secretion of apo-
lipoproteins and responsible for hepatic steatosis [57]. Modest
consistent upregulations were particularly frequent in the
RNA translation/processing pathway, with significant >1.2-
fold changes for 17 transcripts encoding many proteins of
the small and large ribosomal subunit (Rps2, Rps10, Rps12,
Rps15, Rps16, Rps18, Rps26, Rpsa, Rpl6, Rpl8, Rpl10, Rpl13,
Rpl14, Rpl18, Rpl23, Rpl29, Rpl41), for the 40S small ribo-
some subunit component Gnb2l1 (encoding the RACK1 pro-
tein), the ribosomal biogenesis factor Nop10 (encoding the
Nola3 ribonucleoprotein) and the translation initiation factor
Eif2s2. Other notable changes included a modest increase for
the mRNA decay factor Dcps, given that ATXN2 modulates
the size of P-bodies. Strong >2-fold changes were noted also
for the tRNA-editing factorDeadc1 and forDrbp1/Rbm45, an
RNA-binding factor that aggregates with TDP-43 in ALS
neurons [58]. A marked increase was also found for Ssr1, a
receptor that binds to nascent peptides during translation at the
rER to mediate their membrane translocation (on average 1.8-
fold). The complete microarray transcriptome results were de-
posited in the public database GEO (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE55177) under the accession
number GSE55177. Thus, the main finding from the KO
tissues was that Atxn2 levels correlated inversely with
numerous mRNAs that encode factors of RNA processing/
translation.
Candidate analyses by quantitative PCR and immunoblots
For a candidate-driven quantification of effects at the mRNA
and protein level and for further validation, we employed the
liver from independent animals at age 24 weeks. PABPC1 as a
known protein interactor of ATXN2 was first assessed as a
positive control. A significant upregulation was demonstrable
by quantitative immunoblots (Fig. 1a) as previously published
for a cell line with ATXN2 knockdown [30], and here, through
the use of quantitative real-time reverse transcriptase PCR
(qPCR), also a subtle significant increase was detected at the
mRNA level (Fig. 1b).
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To distinguish whether ATXN2 has only strong effects on
few translation factors, or whether the modest effects in di-
verse aspects of translation are also valid, we then prioritized
12 factors in the ribosome/translation pathway to represent
ribosomal biogenesis (Nop10), small and large ribosome sub-
units (Rps10 and Rps18, Rpl14 and Rpl18), small ribosomal
subunit interactors (Gnb2l1), translation initiation (Eif2s2,
Eif3s6, Eif4b) and rER membrane translocation (Srp14,
Ssr1, Sec61b). The latter candidates were also upregulated in
the transcriptome surveys but had missed significance after
multiple testing corrections in all tissue/age conditions. For
all these factors, significant upregulations were consistently
reproduced by qPCR (12 Atxn2−/− versus 12 Atxn2+/+), which
exceeded the fold-change effect size that had been observed
previously for Pabpc1 (Fig. 2).
Although quantitative immunoblot studies have difficulties
to detect changes lower than 2-fold due to non-linear sigmoid
membrane binding and enzyme kinetics, we attempted valida-
tion at the protein level for candidates where specific antibod-
ies are available. Protein soluble in RIPA buffer (which brings
cytosolic factors into solution) did not reveal any significant
changes, but proteins solubilized from tissue after SDS treat-
ment (which brings membrane-associated factors into solu-
tion) exhibited significant upregulations (in 7 Atxn2−/− versus
7 Atxn2+/+ tissues) for NOP10, RPS3, RPS6, RPS10, RPS18
and GNB2L1/RACK1 (Fig. 3). These immunoblot observa-
tions might suggest that ATXN2 has a stronger influence on
ribosomes in association with the membranes of the endoplas-
mic reticulum than on free ribosomes and polysomes in the
cytosol.
Thus, the validation studies corroborate the transcriptome
surveys and extend previous reports that ATXN2 interacts
with rER ribosome/translation complex elements [26, 29,
30, 41, 43–45, 59], demonstrating ATXN2 to modify their
mRNA and protein levels.
Ataxin-2 deficiency enhances S6 phosphorylation
and impairs global protein synthesis
In order to understand whether these mRNA changes enhance
ribosomal translation activity or are part of a compensatory
effort to maintain translation homeostasis and to elucidate at
which step within this pathway the ATXN2 deficiency might
lead to a block, translation control and global protein synthesis
were investigated in cells from 3 Atxn2−/− versus 3 Atxn2+/+
mice. Because public databases on oligonucleotide microar-
rays and on serial analysis of gene expression (SAGE) docu-
ment moderate Atxn2 expression in skin and given that our
preliminary experiments confirmed substantial Atxn2 expres-
sion in skin fibroblasts [25], we employed mouse embryonal
fibroblasts (MEFs). The experiments focused on ribosomal S6
protein as keymodulator of translation initiation, which shows
perfect co-sedimentation with ATXN2 in the brain [26]. As a
first cellular phenotype, the translation control was investigat-
ed in KO versus WT MEFs by assessing the phosphorylation
of S6 after 24-h serum deprivation (basal state) and after 10-
min incubation with insulin (maximal state). A trend to in-
creased phospho-S6 levels was observed at basal state (2.56-
fold, p=0.072), the increase becoming significant after insulin
treatment (2.63-fold, p=0.0097) (Fig. 4a). As the S6 kinase
activity controls the ribosomal biogenesis transcriptional pro-
gram [60], these experimental data are in agreement with the
previous expression effects, jointly suggesting that the KO
cells make enhanced efforts for mRNA translation.
S6 phosphorylation has been reported to modulate assem-
bly of the translation initiation complex [61], while S6 dele-
tion was found to influence cell cycle progression after mito-
gen stimulation more than cell size growth [62, 63]. As a
Fig. 1 ATXN2 KO upregulates levels of PABPC1 protein and mRNA. a
A significant upregulation of the PABPC1/beta-ACTIN protein ratio in
KO liver at age 6 months (7 Atxn2−/− versus 7 Atxn2+/+ tissues) was
detected, as shown in a bar graph above and in an immunoblot below. b
qPCR showed a subtle, but significant upregulation for the ratio Pabpc1/
Tbp in KO liver at 6 months
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second cellular phenotype therefore, general protein synthesis
was investigated through incorporation rates of radioactively
labelled amino acids into newly synthesized proteins of MEF
cells. The absence of ATXN2 led to a moderate reduction of
incorporation rates by 34 % (p=0.029), similar to the effect of
the mTOR kinase inhibitor drug rapamycin (reduction 37 %),
while the translation elongation inhibitor drug cycloheximide
(CHX) produced a complete suppression (by 98 %) (Fig. 4b).
Thus, in spite of the elevated cellular ribosomal machinery
and the enhanced translation signalling, the absence of
ATXN2 caused a decrease in global protein synthesis rates.
Discussion
We conducted an unbiased study to clarify, whether ATXN2
modulates specific RNAs or has global effects, and whether it
acts as repressor or activator of translation. In view of the
presence of ATXN2 as RNA-binding protein in stress gran-
ules, an ATXN2 role as a repressor of translation had been
discussed by experts [64]. In contrast, recent experimental
assessment of this postulate showed ATXN2 to act on the
PERIOD transcript as an activator of translation rate [43,
44], and conversely, the depletion of ATXN2 was observed
Fig. 2 ATXN2 KO upregulates mRNAs of ribosomal/translation factors
in qPCR. Modestly but significantly increased transcript levels were con-
sistently found in qPCR of KO liver at age 6 months (12 Atxn2−/− versus
12 Atxn2+/+) for twelve factors that represent ribosomal biogenesis
(Nop10), ribosomal small subunit (Rps10, Rps18), ribosomal large
subunit (Rpl14, Rpl18), ribosome association with translation factors
(Gnb2l1), translation initiation complex (Eif2s2, Eif3s6, Eif4b) and rER
membrane translocation (Srp14, Ssr1, Sec61b). Tbp served as loading
control to normalize the levels of the candidate
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to reduce the stability and translation of AU-rich element con-
taining mRNAs in vitro and in silico [59, 65]. Beyond such an
effect on an individual mRNA, our data now consistently
show global translation effects of ATXN2, as expected for a
protein interactor of PABPC1. The absence of ATXN2 en-
hanced the abundance of the translation machinery and also
the generic signals driving translation. In cells under growth
stimulation, ATXN2 depletion potentiated the phosphoryla-
tion drive of translation, but in spite of this effort, the overall
amino acid incorporation rates during protein synthesis were
deficient. Thus, the formation of stress granules in times of
cellular stress, with the sequestration of ATXN2/PABPC1/the
small ribosomal subunit/mRNAs, may be interpreted as par-
allel efforts to reduce translational activity.
The formation of stress granules in dependence of ATXN2
appears to be highly conserved between man and yeast. In
S. cerevisiae, the translational activator target of rapamycin
complex 1 (TORC1) was found sequestrated together with
the ATXN2 orthologue Pbp1 into stress granules [51]. Indeed,
our murine data confirm that ATXN2 interacts with mamma-
lian target of rapamycin (mTOR) signalling pathways, be-
cause ribosomal S6 phosphorylation is mTOR dependent
[66] and is excessive in Atxn2−/− MEFs after insulin stimula-
tion. Thus, yeast and mouse evidence jointly suggests that
ATXN2 blunts mTOR signalling. It is also important to note
that stress granule components can be recruited to lipid drop-
lets. A study of hepatitis C virus (HCV) infection in a
hepatocyte cell line showed the HCV production factory
around lipid droplets to sequester P-body elements and the
stress granule components ATXN2, PABPC1 and G3BP1
[67]. Thus, the pathways of mRNA quality control and decay
are intertwined with the recruitment of lipid energy reserves
during periods of cell stress. Therefore, our observation that
ATXN2 depletion modifies the abundance of the lipid droplet
regulators perilipin-3 (Plin3) and of the apolipoprotein secre-
tion factor Mttp, of the RNA decay factor Dcps and of the
tRNA splicing factor Lsm12 appears meaningful in this con-
text. These current findings were very similar to our previous
observations in a project on the stress granule seeding factor
TIA-1: the transcriptome profiling of mouse brain with genet-
ic Tia1-ablation demonstrated from 1.6-fold until 3.5-fold al-
terations of the lipid droplet trafficking factor perilipin-4
(Plin4), the RNA decay factor Dcp1b and the tRNA splicing
factor Tsen2 [68]. The relevance of ATXN2 for the secretion
of lipid trafficking factors was also shown in a recent study of
the blood plasma proteome of SCA2 patients, where the sig-
nificant dysregulation of 9 factors was documented, including
a 4-fold decrease in apolipoprotein C3, a 3-fold decrease in
apolipoprotein A1, a 2-fold decrease in aplipoprotein C2
and a > 4-fold increase in apolipoprotein E [69]. Ataxin-2
therefore appears to play a double role for mRNA translation
and processing on the one hand, and for lipid recruitment
and storage on the other hand, two crucial pathways during
cell stress.
Fig. 3 ATXN2 KO upregulates proteins of ribosomal/translation factors.
Modestly but significantly enhanced protein levels were consistently
found in quantitative immunoblots of RIPA-insoluble, but SDS-soluble
extracts from KO liver at age 6 months (7 Atxn2−/− versus 7 Atxn2+/+) for
six factors that represent ribosomal biogenesis (NOP10/NOLA3),
components of the 40S small ribosomal subunit (RPS3, RPS6, RPS10,
RPS18), and the association between the 40S small ribosomal subunit and
translation initiation factors (GNB2L1/RACK1). Beta-ACTIN served as
loading control to normalize the levels of the candidate
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The mechanistic details, how the absence of ATXN2 exerts
effects on translation and on the abundance of the ribosomal
translation factors, remain unclear. ATXN2 could modulate
the mRNA levels through direct interaction and decay modu-
lation [59] or through its reported action as transcription factor
in the nucleus [31]. But the upregulated abundance of trans-
lation factors could simply represent an indirect compensatory
effort to overcome a blocked translation step. To our knowl-
edge, only two transcription factors were previously reported
to control in coordinated manner the transcript levels of
ribosomal proteins and eukaryotic translation initiation/
elongation factors in mammals in a coordinated manner. First,
epidermal growth factor (EGF) stimulation via ERK phos-
phorylation of the transcription factor upstream binding factor
(UBF) leads to an immediate activation of ribosomal tran-
scription [70]. This can easily be linked to ATXN2, as we
already showed the internalisation of activated EGF receptors
and the levels of associated signalling molecules GRB2 and
SRC to bemodified bymutations of ATXN2 [24, 25]. Second,
overexpression of the UBF co-activators c-Myc [71] or n-Myc
within 4 h enhances the transcript levels of most ribosomal
proteins [72]. This observation also ties in with our data about
ATXN2 effects on ribosomal transcripts, because ATXN2
overexpression antagonizes n-Myc gene amplification, thus
promoting the spontaneous regression of pediatric neuroblas-
toma tumors [73]. Both c-Myc translation and UBF levels are
known to depend on mTOR signalling [74]. Thus, ATXN2
seems to act in concert with UBF, n-Myc and mTOR in mod-
ifying the transcriptional control of ribosomal machinery. In
conclusion, a translation block due to ATXN2 depletion could
trigger efforts to maintain protein synthesis within a range of
homeostasis via these transcription factors and could explain
the observations as indirect effects.
It remains unclear whether the changes of ribosomal trans-
lation and protein synthesis in ATXN2-ablated tissue underlie
the previously reported neuroprotective effect of ATXN2 de-
ficiency for motor neuron degeneration [4]. Indeed, recent
screens in S. cerevisiae, C. elegans and D. melanogaster doc-
umented a role for ATXN2 as a generic modifier that affects
multiple if not all neurodegenerative diseases, including sev-
eral polyQ-triggered spinocerebellar ataxias [8]. It is therefore
interesting to note that the dosage of ribosomes and translation
factors was found to act as modifier of polyQ expansion pro-
tein aggregation, as recently shown in systematic C. elegans
and H. sapiens studies [75]. Given that protein synthesis is a
very energy-consuming process, its modulation may an im-
portant determinant of cell metabolism and atrophy. Thus, our
novel data might be relevant for the neurodegenerative disease
process and might provide neuroprotective insights.
While no data are available yet from patient tissues of the
rare disease SCA2 regarding ribosomal translation, it is tempt-
ing to speculate that the SCA2-specific neurodegeneration
pattern might be partially explained through the influence of
ATXN2 mutations on global protein synthesis. The affected
cerebellar Purkinje and brainstem olivo-pontine neurons, mid-
brain dopaminergic neurons, as well as spinal and cortical
motor neurons are among the largest neurons of the nervous
system, with characteristically large rER complexes (named
Nissl substance or tigroid bodies) for ribosomal translation.
These magnocellular neurons are the first to undergo cell
death in SCA2, already at presymptomatic and initial stages
of disease [76–79]. Thus, our findings are in agreement with
known features of ATXN2-associated diseases, but
Fig. 4 Ataxin-2 effects on global translation regulation and activity. a
The ratio of ribosomal S6 phosphorylation normalized to total S6 content
increased in Atxn2−/− cells. MEF cells from WT or KO animals were
serum-starved for 24 h, and S6 phosphorylation was measured at basal
condition (bas) or after incubation with insulin (Ins) over 10 min. A trend
towards increased S6 phosphorylationwas observed inKOMEFs at basal
condition after starvation, and a highly significant increase of S6 phos-
phorylation was measured after insulin treatment (n=2–3 MEF lines per
genotype). b ATXN2 deficiency reduced basal mRNA translational ac-
tivity. The incorporation of [S35]-labelled methionine/cysteine was quan-
tified in MEFs to assess global protein synthesis rates. Cycloheximide
(CHX) or rapamycin were applied 90 min prior to labelling to some cell
lines. KO MEFs showed a reduction in protein synthesis by 34 % in
comparison toWTMEFs (n=6MEF lines per genotype in 3 independent
technical replicates). As control and comparison, the translation elonga-
tion inhibitor CHX diminished translation to 2 %, the mTOR pathway
inhibitor rapamycin to 63 % (n=2 MEF lines)
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experimental verification in human has to await the availabil-
ity of frozen nervous tissue affected by this rare disorder.
Overall, our mouse mutant data show that the chronic de-
pletion of ATXN2 impairs the rate of amino acid incorporation
during mRNA translation for protein synthesis, while trigger-
ing responses in the liver and cerebellum to maintain global
translation and bioenergetics through the transcriptional up-
regulation of specific factors in the pathways of ribosomal
biogenesis/translation initiation/ER secretion/lipid trafficking.
Materials and methods
Mouse breeding and dissection
Animals were bred and aged in individually ventilated cages
with continuous health monitoring, 4–6 animals per cage, un-
der a 12-h light cycle with food (Ssniff M-Z, calories from
protein 36 %, fat 11 % and carbohydrates 53 %) and water
provided ad libitum.Mice were housed in accordance with the
German Animal Welfare Act, the Council Directive of 24
November 1986 (86/609/EWG) with Annex II and the
ETS123 (European Convention for the Protection of Verte-
brate Animals) at the FELASA-certified Central Animal Fa-
cility (ZFE) of the Frankfurt University Medical School. All
analyses were performed on male mice with a mixed C57BL/
6_129/Ola background. Genotyping was performed with tail
biopsies by PCR with three sets of primers as previously
described [9].
RNA preparation and cDNA synthesis
After cervical dislocation, the cerebellum and liver were dis-
sected from homozygous wild-type (Atxn2+/+) and knockout
(Atxn2−/−) mice at 6 and 24 weeks of age. Total RNA was
extracted from these tissues by homogenization in 1 ml of
ny). One-microgram total RNAwas digested with a DNase I
Amplification Grade Kit (Invitrogen, Karlsruhe) in a reaction
volume of 10 μl per tube in order to eliminate DNA during
RNA purification prior to reverse transcription (RT-PCR) am-
plification. cDNA synthesis was performed with the
Fermentas Life Sciences First Strand cDNA Synthesis Kit as
instructed in the manual.
Unbiased oligonucleotide microarray chip transcriptome
profiling
The cerebellum and liver were dissected from 4 male homo-
zygous wild-type (Atxn2+/+) and 4 knockout (Atxn2−/−) mice
at 6 and 24 weeks of age. Double-stranded cDNA was syn-
thesised from 1 μg of total RNA and was linearly amplified
and biotinylated using the One-Cycle Target Labeling Kit
(Affymetrix, Santa Clara, CA) according to the manufac-
turer’s instructions. Fifteen micrograms of labelled and
fragmented cRNA was hybridized to MOE430 2.0 Gene
MFTServices (Tübingen), thus detecting 39,000 transcripts
and variants corresponding to 34,000 mouse genes. After hy-
bridization, the arrays were washed and stained in a Fluidics
Station 450 (Affymetrix) with the recommended washing pro-
cedure. Biotinylated cRNA bound to target molecules was
detected with streptavidin-coupled phycoerithrin, biotinylated
anti-streptavidin IgG antibodies and again streptavidin-
coupled phycoerithrin according to the protocol. Arrays were
scanned using the GCS3000 Gene Chip scanner (Affymetrix)
and GCOS 1.4 software. Scanned images were subjected to
visual inspection to control for hybridisation artifacts and
proper grid alignment and analysed with Genespring (Agilent
Technologies) and Expression Console MAS5, Microarray
Suite 5.0 (Affymetrix), to generate report files for quality con-
trol. To define the influence of the factor genotype or age on
the transcriptome, linear models were applied [80, 81]. For the
mathematical-statistical assessment of data, their visualisation
and functional correlation, the software platform R (version
2.5.0) and the pertinent bioconductor packages Affy,
Just.RMA, and Limma (www.bioconductor.org) and diverse
tools at the panther website (http://www.pantherdb.org) were
used. Initially, the expression data from all chips were
normalized with the RMA (Robust Microchip Average) to
yield log2-transformed signal values. Global gene expression
was compared between chips using scatter plots and Pearson’s
R correlation coefficients. The signal values were then aver-
aged for the individual subgroups, and differences in expres-
sion level were calculated in log2 space (M-values). Differ-
ences between subgroups were extracted as contrasts and
analysed with the moderated F-test (empirical Bayes method)
including a correction step for multiple testing with the 5 %
FDR-based method of Benjamini and Hochberg [82]. To at-
tribute significant effects to individual genes, a decision ma-
trix was generated based on the function decide tests within
the Limma option nestedF, where significant upregulations or
downregulations are represented by values of 1 or −1,
respectively.
Validation of quantitative real-time reverse transcriptase
polymerase chain reaction
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Trizol® Reagent per 50–100 mg of tissue using a Pellet Pes-
tle® Motor tissue homogenizer (Kontes, The Glass Compa-
Chip® oligonucleotide microarrays (Affymetrix) at
Quantitative real-time reverse transcriptase polymerase chain
reaction (qPCR) was performed using a GeneAmp® 5700
Sequence Detection System (Applied Biosystems, CA USA)
with 96-well Optical Reaction Plates (Applied Biosystems,
CA USA). Twenty-microliter final reaction volume per well
contained 25–30 ng cDNA, TaqMan® Universal PCR Master
Mix, No AmpErase® UNG and primers and probes in pre-
assays were used: Pabpc1, Mm00849569_s1; Nop10,
Mm00777618_g1; Rps10, Mm02391992_g1; Rps18,
Mm02601777_g1; Rpl14, Mm00782569_s1; Rpl18,
Mm01197265_g1; Gnb2l1 , Mm01291968_g1 and
Mm01291084_m1; Eif2s2, Mm00782672_s1; Eif3e,
Mm01700222_g1; Eif3s6, Mm01700222_g1; Eif4b,
Mm00778003_s1; Sec61b, Mm00834975_g1; Srp14,
Mm00726104_s1; Ssr1, Mm00503135_m1. All assays were
run in triplicate. Tbp (Mm 00446973_m1) was used as an
endogenous control in all experiments and was run in wells
separate from the target gene assays. The PCR conditions were
50 °C for 2 min and 95 °C for 10 min followed by 40 cycles at
95 °C for 15 s and 60 °C for 40 s. Analysis of relative gene
expression data was performed using the ΔΔCT method.
Quantitative immunoblot analysis
Liver tissue from 4 wild-type and 4 homozygous Atxn2
knockout mice was weighed and processed. It was homoge-
nized with a motor pestle in 10 vol. RIPA buffer [50 mMTris–
HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1 % Igepal CA-630 (Sigma), 0.5 % sodium deoxycholate,
0.1 % SDS, 1 mM PMSF, Complete Protease Inhibitor Cock-
tail (Roche)] and incubated on ice for 15 min. After centrifu-
gation at 4 °C and 16,000×g for 20 min, the supernatant was
stored (RIPA-soluble fraction), and the remaining pellet was
dissolved in ½ vol. 2× SDS buffer [137 mM Tris–HCl
(pH 6.8), 4 % SDS, 20 % glycerol, Complete Protease Inhib-
itor Cocktail (Roche)] by sonification followed by 10 min of
centrifugation at 16,000×g. The resulting supernatant was
stored as RIPA-insoluble fraction.
The protein concentration of the samples was measured
using the standard Bradford protein assay [83]. Bovine serum
albumin (BSA) dilutions were used as standards to construct
the calibration curve. Prior to every gel electrophoresis exper-
iment, 2× loading buffer was added to the tissue homogenates,
which were then heated at 95 °C for 5 min.
The samples were analysed by sodium dodecylsulfate
polyacrylamide gel electrophoresis (SDS-PAGE) according
to Laemmli, loading 10 μg protein per lane [84]. The time
required for transfer of the protein pattern to the PVDF mem-
brane at 100 V varied between half an hour for small proteins
<20 kDa and an hour for larger proteins. After electroblotting,
unspecific binding sites on the PVDF membrane were
blocked for 1 h at room temperature in a solution of 5 % dry
milk powder in PBS containing 0.05 % Tween 20 (PBS/T)
and then incubated over night at 4 °C with the following
antibodies diluted in a mixture of 2.5 ml PBS/T and 2.5 ml
of 5 % dry milk powder in PBS/T: mouse monoclonal anti-
Ataxin-2 (1:500, BD Biosciences), rabbit polyclonal anti-
Phospho-eIF4B (1:1000, Cell Signaling), rabbit polyclonal
anti-PABP (1:1000, Abcam UK), rabbit monoclonal anti-
NOP10 (1:1000, LSBio), rabbit polyclonal anti-RPL8
(1:2000, GeneTex), mouse polyclonal anti-RPL18 (1:500,
Abnova, Taiwan Corporation), rabbit polyclonal ribosomal
protein anti-L26 (1:1000, Cell Signaling), rabbit polyclonal
ribosomal protein anti-S3 (1:1000, Cell Signaling), rabbit
polyclonal ribosomal protein anti-S6 (1:1000, Cell Signaling),
rabbit polyclonal ribosomal protein anti-S10 (1:2000,
ThermoFisher), rabbit polyclonal anti-RPS18 (1:1000, Acris),
rabbit polyclonal anti-RACK1 (1:1000, Cell Signaling),
mouse monoclonal anti-RACK1 (1:2500, BD Transduction),
rabbit polyclonal anti-EIF2S2 (1:2000, proteintech), rabbit
polyclonal anti-SRP14 (1:1000, ProteinTech Group, Inc.),
rabbit polyclonal anti-SRP14 (1:300, Assay Designs), mouse
monoclonal anti-SSR1 (1:500, Novus Biologicals) antibody
and mouse monoclonal anti-beta-ACTIN (1: 10000, Sigma)
as a loading control. Following incubation with the primary
antibody, the membranes were washed (3×10 min in PBS/T)
and then incubated with the secondary antibodies conjugated
to horse radish peroxidase (HRP) for 1 h at room temperature
(anti-mouse-IgG-horseradish peroxidase (1:10,000, GE
Healthcare), anti-rabbit-IgG-horseradish peroxidase (1:10,
000, Amersham Biosciences), donkey-anti-goat-IgG-
horseradish peroxidase (1:30,000, Santa Cruz Biotechnology,
Inc.). After binding of the secondary antibody, the blots were
washed again in PBS/T (3×10 min), and ECL detection
(Supersignal West Pico Chemiluminescent Substrate, Pierce)
was performed at room temperature according to the manu-
facturer’s protocol, with varying exposure times to avoid film
sensitivity or saturation problems as well as non-linear effects.
The images were digitalized on a scanner (Epson) and densi-
tometry performed with the proprietary ImageMaster Total
Lab 2.00 software (AmershamPharmacia). After normaliza-
tion of candidate protein values versus beta-actin values from
the identical membrane in EXCEL, the changes were evalu-
ated in GraphPad statistics and plotting.
Ribosomal S6 phosphorylation
Mouse embryonal fibroblasts (MEFs) were generated as previ-
ously described [24]. To investigate the ribosomal S6 phosphor-
ylation status in MEFs, confluent cells were serum-starved for
24 h, and either left untreated or incubated with 100 nM insulin
for 10min. The phosphorylation status of S6wasmeasuredwith
the PathScan Phospho-S6 Ribosomal Protein (Ser235/236)
Sandwich ELISA Kit (#7205, Cell Signaling, Danvers, USA)
according to manufacturer’s protocol. One micromolar PMSF
was added to the cell lysis buffer to prevent protein degradation.
Global protein synthesis after deprivation and stimulation
in vitro
For the analysis of global protein synthesis rates, 2×105MEFs
were seeded on 6-well plates the day before the experiment.
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designed TaqMan® Gene Expression Assays. The following
Cells were then deprived of methionine and cysteine for
30 min and labelled by addition of 20 μCi/ml [35S] EasyTag
Express Protein Labeling Mix for 40 min (Perkin Elmer, Wal-
tham, MA, USA). For the treatment with inhibitors, cells were
supplemented 30 min before the labelling with 1 μM cyclo-
heximide (CHX, Sigma-Aldrich, Munich, Germany) or
20 nM rapamycin (LC Laboratories, Woburn, MA, USA).
After washing twice with ice-cold PBS, cells were lysed in
RIPA and precipitated with ice-cold 10 % TCA on GF/C fil-
ters (Whatman, Dassel, Germany). After washing twice with
ice-cold 5 % TCA and once with methanol, filters were dried
and subjected to liquid scintillation counting (Perkin-Elmer,
Boston, USA).
Statistical analysis
The Graph-Pad software package (version 4.03, GraphPad
Software Inc., San Diego, California, USA) was used to per-
form the non-parametric Mann-Whitney test or the parametric
Student’s t test to represent data with bar graphs and to illus-
trate mean values and standard deviations. Significant differ-
ences were highlighted with asterisks (*p<0.05; **p<0.01;
***p<0.005).
Acknowledgments We are grateful to Bianca Scholz for technical as-
sistance. The project was financially supported by the DFG (AU96/14-1
and AU96/13-1).
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y et al (1996)
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with
high sensitivity to expanded CAG/glutamine repeats. Nat Genet 14:
285–291
2. Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN et al
(1996) Moderate expansion of a normally biallelic trinucleotide re-
peat in spinocerebellar ataxia type 2. Nat Genet 14:269–276
3. Sanpei K, Takano H, Igarashi S, Sato T, Oyake M et al (1996)
Identification of the spinocerebellar ataxia type 2 gene using a direct
identification of repeat expansion and cloning technique, DIRECT.
Nat Genet 14:277–284
4. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS et al
(2010) Ataxin-2 intermediate-length polyglutamine expansions are
associated with increased risk for ALS. Nature 466:1069–1075
5. Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I et al (2012) The
modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 inter-
mediate polyglutamine expansions is a specific effect. Neurobiol Dis
45:356–361
6. Charles P, Camuzat A, Benammar N, Sellal F, Destee A et al (2007)
Are interrupted SCA2 CAG repeat expansions responsible for par-
kinsonism? Neurology 69:1970–1975
7. Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo
MM et al (2011) Ataxin-2 repeat-length variation and neurodegener-
ation. Hum Mol Genet 20:3207–3212
8. Na D, Rouf M, O’Kane CJ, Rubinsztein DC, Gsponer J (2013)
NeuroGeM, a knowledgebase of genetic modifiers in neurodegener-
ative diseases. BMC Med Genet 6:52
9. Lastres-Becker I, Brodesser S, Lutjohann D, Azizov M, Buchmann J
et al (2008) Insulin receptor and lipid metabolism pathology in
ataxin-2 knock-out mice. Hum Mol Genet 17:1465–1481
10. Kiehl TR, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP et al
(2006) Generation and characterization of Sca2 (ataxin-2) knockout
mice. Biochem Biophys Res Commun 339:17–24
11. Figueroa KP, Farooqi S, Harrup K, Frank J, O’Rahilly S et al (2009)
Genetic variance in the spinocerebellar ataxia type 2 (ATXN2) gene
in children with severe early onset obesity. PLoS One 4:e8280
12. Wtcc C (2007) Genome-wide association study of 14,000 cases of
seven common diseases and 3,000 shared controls. Nature 447:661–
678
13. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB et al (2013)
Loci influencing blood pressure identified using a cardiovascular
gene-centric array. Hum Mol Genet 22:1663–1678
14. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ et al (2009)
Genome-wide association study of blood pressure and hypertension.
Nat Genet 41:677–687
15. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M et al
(2009) Genome-wide association study identifies eight loci associat-
ed with blood pressure. Nat Genet 41:666–676
16. Fox ER, Young JH, Li Y, Dreisbach AW, Keating BJ et al (2011)
Association of genetic variation with systolic and diastolic blood
pressure among African Americans: the Candidate Gene
Association Resource study. Hum Mol Genet 20:2273–2284
17. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD et al
(2011) Genetic variants in novel pathways influence blood pressure
and cardiovascular disease risk. Nature 478:103–109
18. Affaitati A, de Cristofaro T, Feliciello A, Varrone S (2001)
Identification of alternative splicing of spinocerebellar ataxia type 2
gene. Gene 267:89–93
19. Huynh DP, Del Bigio MR, Ho DH, Pulst SM (1999) Expression of
ataxin-2 in brains from normal individuals and patients with
Alzheimer’s disease and spinocerebellar ataxia 2. Ann Neurol 45:
232–241
20. Nechiporuk T, Huynh DP, Figueroa K, Sahba S, Nechiporuk A et al
(1998) The mouse SCA2 gene: cDNA sequence, alternative splicing
and protein expression. Hum Mol Genet 7:1301–1309
21. Scoles DR, Pflieger LT, Thai KK, Hansen ST, Dansithong W et al
(2012) ETS1 regulates the expression of ATXN2. Hum Mol Genet
21:5048–5065
22. Ralser M, Nonhoff U, Albrecht M, Lengauer T, Wanker EE et al
(2005) Ataxin-2 and huntingtin interact with endophilin-A com-
plexes to function in plastin-associated pathways. Hum Mol Genet
14:2893–2909
23. Lim J, Hao T, Shaw C, Patel AJ, Szabo G et al (2006) A protein-
protein interaction network for human inherited ataxias and disorders
of Purkinje cell degeneration. Cell 125:801–814
24. Nonis D, Schmidt MH, van de Loo S, Eich F, Dikic I et al (2008)
Ataxin-2 associates with the endocytosis complex and affects EGF
receptor trafficking. Cell Signal 20:1725–1739
25. Drost J, Nonis D, Eich F, Leske O, Damrath E et al (2013) Ataxin-2
modulates the levels of Grb2 and SRC but not ras signaling. J Mol
Neurosci MN 51:68–81
26. van de Loo S, Eich F, Nonis D, Auburger G, Nowock J (2008)
Ataxin-2 associates with rough endoplasmic reticulum. Exp Neurol
215:110–118
190 Neurogenetics (2015) 16:181–192
27. Huynh DP, Yang HT, Vakharia H, Nguyen D, Pulst SM (2003)
Expansion of the polyQ repeat in ataxin-2 alters its Golgi localiza-
tion, disrupts the Golgi complex and causes cell death. Hum Mol
Genet 12:1485–1496
28. Huynh DP, Figueroa K, Hoang N, Pulst SM (2000) Nuclear locali-
zation or inclusion body formation of ataxin-2 are not necessary for
SCA2 pathogenesis in mouse or human. Nat Genet 26:44–50
29. Satterfield TF, Pallanck LJ (2006) Ataxin-2 and its Drosophila ho-
molog, ATX2, physically assemble with polyribosomes. Hum Mol
Genet 15:2523–2532
30. Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D et al (2007)
Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and
interferes with P-bodies and stress granules. Mol Biol Cell 18:1385–
1396
31. Hallen L, Klein H, Stoschek C,Wehrmeyer S, Nonhoff U et al (2011)
The KRAB-containing zinc-finger transcriptional regulator ZBRK1
activates SCA2 gene transcription through direct interaction with its
gene product, ataxin-2. Hum Mol Genet 20:104–114
32. Albrecht M, Lengauer T (2004) Survey on the PABC recognition
motif PAM2. Biochem Biophys Res Commun 316:129–138
33. Derry MC, Yanagiya A, Martineau Y, Sonenberg N (2006)
Regulation of poly(A)-binding protein through PABP-interacting
proteins. Cold Spring Harb Symp Quant Biol 71:537–543
34. Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H et al
(2005) An integrative approach to gain insights into the cellular func-
tion of human ataxin-2. J Mol Biol 346:203–214
35. Kozlov G, Trempe JF, Khaleghpour K, Kahvejian A, Ekiel I et al
(2001) Structure and function of the C-terminal PABC domain of
human poly(A)-binding protein. Proc Natl Acad Sci U S A 98:
4409–4413
36. Mangus DA, Amrani N, Jacobson A (1998) Pbp1p, a factor
interacting with Saccharomyces cerevisiae poly(A)-binding protein,
regulates polyadenylation. Mol Cell Biol 18:7383–7396
37. Lessing D, Bonini NM (2008) Polyglutamine genes interact to mod-
ulate the severity and progression of neurodegeneration in
Drosophila. PLoS Biol 6:e29
38. Neuwald AF, Koonin EV (1998) Ataxin-2, global regulators of bac-
terial gene expression, and spliceosomal snRNP proteins share a con-
served domain. J Mol Med 76:3–5
39. Shibata H, Huynh DP, Pulst SM (2000) A novel protein with
RNA-binding motifs interacts with ataxin-2. Hum Mol Genet
9:1303–1313
40. Farg MA, Soo KY, Warraich ST, Sundaramoorthy V, Blair IP et al
(2013) Ataxin-2 interacts with FUS and intermediate-length
polyglutamine expansions enhance FUS-related pathology in amyo-
trophic lateral sclerosis. Hum Mol Genet 22:717–728
41. Sudhakaran IP, Hillebrand J, Dervan A, Das S, Holohan EE et al
(2014) FMRP and Ataxin-2 function together in long-term olfactory
habituation and neuronal translational control. Proc Natl Acad Sci U
S A 111:E99–E108
42. Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM et al
(2012) Insights into RNA biology from an atlas of mammalian
mRNA-binding proteins. Cell 149:1393–1406
43. Lim C, Allada R (2013) ATAXIN-2 activates PERIOD translation to
sustain circadian rhythms in Drosophila. Science 340:875–879
44. Zhang Y, Ling J, Yuan C, Dubruille R, Emery P (2013) A role for
Drosophila ATX2 in activation of PER translation and circadian be-
havior. Science 340:879–882
45. McCann C, Holohan EE, Das S, Dervan A, Larkin A et al (2011) The
Ataxin-2 protein is required for microRNA function and synapse-
specific long-term olfactory habituation. Proc Natl Acad Sci U S A
108:E655–E662
46. Mangus DA, Smith MM, McSweeney JM, Jacobson A (2004)
Identification of factors regulating poly(A) tail synthesis and matu-
ration. Mol Cell Biol 24:4196–4206
47. Kimura Y, Irie K (2013) Pbp1 is involved in Ccr4- and Khd1-
mediated regulation of cell growth through association with ribosom-
al proteins Rpl12a and Rpl12b. Eukaryotic Cell 12:864–874
48. Albrecht M, Lengauer T (2004) Novel Sm-like proteins with long C-
terminal tails and associated methyltransferases. FEBS Lett 569:18–
26
49. Fleischer TC, Weaver CM,McAfee KJ, Jennings JL, Link AJ (2006)
Systematic identification and functional screens of uncharacterized
proteins associated with eukaryotic ribosomal complexes. Genes Dev
20:1294–1307
50. Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M et al (2002)
Functional organization of the yeast proteome by systematic analysis
of protein complexes. Nature 415:141–147
51. Takahara T, Maeda T (2012) Transient sequestration of TORC1 into
stress granules during heat stress. Mol Cell 47:242–252
52. Swisher KD, Parker R (2010) Localization to, and effects of Pbp1,
Pbp4, Lsm12, Dhh1, and Pab1 on stress granules in Saccharomyces
cerevisiae. PLoS One 5:e10006
53. Kimball SR, Horetsky RL, Ron D, Jefferson LS, Harding HP (2003)
Mammalian stress granules represent sites of accumulation of stalled
translation initiation complexes. Am J Physiol Cell Physiol 284:
C273–C284
54. Martineau Y, Derry MC, Wang X, Yanagiya A, Berlanga JJ et al
(2008) Poly(A)-binding protein-interacting protein 1 binds to eukary-
otic translation initiation factor 3 to stimulate translation. Mol Cell
Biol 28:6658–6667
55. Martineau Y, Wang X, Alain T, Petroulakis E, Shahbazian D et al
(2014) Control of Paip1-eukayrotic translation initiation factor 3 in-
teraction by amino acids through S6 kinase. Mol Cell Biol 34:1046–
1053
56. Fan B, Gu JQ, Yan R, Zhang H, Feng J et al (2013) High glucose,
insulin and free fatty acid concentrations synergistically enhance
perilipin 3 expression and lipid accumulation in macrophages.
Metab Clin Exp 62:1168–1179
57. Raabe M, Veniant MM, Sullivan MA, Zlot CH, Bjorkegren J et al
(1999) Analysis of the role ofmicrosomal triglyceride transfer protein
in the liver of tissue-specific knockout mice. J Clin Invest 103:1287–
1298
58. Collins M, Riascos D, Kovalik T, An J, Krupa K et al (2012) The
RNA-binding motif 45 (RBM45) protein accumulates in inclusion
bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal
lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Acta Neuropathol 124:717–732
59. Yokoshi M, Li Q, Yamamoto M, Okada H, Suzuki Y et al (2014)
Direct binding of Ataxin-2 to distinct elements in 3′ UTRs promotes
mRNA stability and protein expression. Mol Cell 55:186–198
60. Chauvin C, Koka V, Nouschi A, Mieulet V, Hoareau-Aveilla C et al
(2013) Ribosomal protein S6 kinase activity controls the ribosome
biogenesis transcriptional program. Oncogene 33:474–483
61. Holz MK, Ballif BA, Gygi SP, Blenis J (2005) mTOR and S6K1
mediate assembly of the translation preinitiation complex through
dynamic protein interchange and ordered phosphorylation events.
Cell 123:569–580
62. Volarevic S, Stewart MJ, Ledermann B, Zilberman F, Terracciano L
et al (2000) Proliferation, but not growth, blocked by conditional
deletion of 40S ribosomal protein S6. Science 288:2045–2047
63. Holland EC, Sonenberg N, Pandolfi PP, Thomas G (2004) Signaling
control of mRNA translation in cancer pathogenesis. Oncogene 23:
3138–3144
64. Anderson P, Kedersha N (2009) RNA granules: post-transcriptional
and epigenetic modulators of gene expression. Nat RevMol Cell Biol
10:430–436
65. Singh A, Minia I, Droll D, Fadda A, Clayton C et al (2014)
Trypanosome MKT1 and the RNA-binding protein ZC3H11: inter-
actions and potential roles in post-transcriptional regulatory net-
works. Nucleic Acids Res 42:4652–4668
Neurogenetics (2015) 16:181–192 191
66. Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator
of nutrient and growth factor signals and coordinator of cell growth
and cell cycle progression. Oncogene 23:3151–3171
67. Ariumi Y, Kuroki M, Kushima Y, Osugi K, Hijikata M et al (2011)
Hepatitis C virus hijacks P-body and stress granule components
around lipid droplets. J Virol 85:6882–6892
68. Heck MV, Azizov M, Stehning T, Walter M, Kedersha N et al (2014)
Dysregulated expression of lipid storage and membrane dynamics
factors in Tia1 knockout mouse nervous tissue. Neurogenetics 15:
135–144
69. Swarup V, Srivastava AK, Padma MV, Moganty RR (2013)
Quantitative profiling and identification of plasma proteins of
spinocerebellar ataxia type 2 patients. Neurodegener Dis 12:199–206
70. Stefanovsky VY, Pelletier G, Hannan R, Gagnon-Kugler T,
Rothblum LI et al (2001) An immediate response of ribosomal tran-
scription to growth factor stimulation in mammals is mediated by
ERK phosphorylation of UBF. Mol Cell 8:1063–1073
71. Poortinga G, Hannan KM, Snelling H, Walkley CR, Jenkins A et al
(2004) MAD1 and c-MYC regulate UBF and rDNA transcription
during granulocyte differentiation. Embo J 23:3325–3335
72. Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC et al
(2001) N-myc enhances the expression of a large set of genes function-
ing in ribosome biogenesis and protein synthesis. Embo J 20:1383–1393
73. Wiedemeyer R, Westermann F, Wittke I, Nowock J, Schwab M
(2003) Ataxin-2 promotes apoptosis of human neuroblastoma cells.
Oncogene 22:401–411
74. Hannan KM, Brandenburger Y, Jenkins A, Sharkey K, Cavanaugh A
et al (2003) mTOR-dependent regulation of ribosomal gene transcrip-
tion requires S6K1 and is mediated by phosphorylation of the
carboxy-terminal activation domain of the nucleolar transcription
factor UBF. Mol Cell Biol 23:8862–8877
75. Teuling E, Bourgonje A, Veenje S, Thijssen K, de Boer J et al (2011)
Modifiers of mutant huntingtin aggregation: functional conservation
of C. elegans-modifiers of polyglutamine aggregation. PLoS currents
3: RRN1255
76. Estrada R, Galarraga J, Orozco G, Nodarse A, Auburger G (1999)
Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 au-
topsies. Acta Neuropathol 97:306–310
77. Velazquez-Perez L, Rodriguez-Labrada R, Canales-Ochoa N,
Montero JM, Sanchez-Cruz G et al (2014) Progression of early fea-
tures of spinocerebellar ataxia type 2 in individuals at risk: a longi-
tudinal study. Lancet Neurol 13:482–489
78. Gierga K, Bürk K, Bauer M, Orozco Diaz G, Auburger G, Schultz C,
Vuksic M, Schöls L, de Vos RA, Braak H, Deller T, Rüb U (2005)
Involvement of the cranial nerves and their nuclei in spinocerebellar
ataxia type 2 (SCA2). Acta Neuropathol 109:617–31
79. Hoche F, Balikó L, den DunnenW, Steinecker K, Bartos L, Sáfrány E,
Auburger G, Deller T, Korf HW, Klockgether T, Rüb U, Melegh B
(2011) Spinocerebellar ataxia type 2 (SCA2): identification of early
brain degeneration in one monozygous twin in the initial disease stage.
Cerebellum 10:245–53
80. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B et al (2003)
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids
Res 31:e15
81. Smyth GK (2005) Limma: linear models for microarray data. In:
Bioinformatics and computational biology solutions using R and
bioconductor R. (Gentleman, V. Carey, S. Dudoit, R. Irizarry, W.
Huber). Springer, New York, pp 397–420
82. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate:
a practical and powerful approach to multiple testing. J R Stat Soc Ser
B 57:289–300
83. Bradford MM (1976) A rapid and sensitive method for the quantita-
tion of microgram quantities of protein utilizing the principle of
protein-dye binding. Anal Biochem 72:248–254
84. Laemmli UK (1970) Cleavage of structural proteins during the as-
sembly of the head of bacteriophage T4. Nature 227:680–685
192 Neurogenetics (2015) 16:181–192
